HSP90AB1 and ovarian cancer: Collectively, these data demonstrate that ME treatment increases the sensitivity of ovarian cancer cells to cisplatin by suppressing HSP90AB1 expression, thereby inhibiting the proliferation, invasion, and migration of ovarian cancer cells.